Codagenix
Farmingdale, US · Founded 2011 · Delaware corporation · 18 employees on LinkedIn · 3 known investors
Find your way into Codagenix
240 people in our graph share verified history with the Codagenix team — schools, employers, funds. One of them is your warm intro.
Alex Bardunlockedknows Steffen Mueller · together at Stony Brook University (overlapped)
×3knows the team · via Stony Brook University
×6knows the team · via University of Cologne
×2knows the team · via King's College London
Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses. The company applies this platform in clinical development, drawing on expertise in virology, computational science, and patient care.
Founders & leadership
Codagenix was founded in 2011 by John Robert Coleman and Steffen Mueller.
JR
John Robert ColemanCo-founder
SM
Steffen MuellerinFounder, President, Chief Scientific OfficerMueller founded Codagenix in 2009 and has also served as its president. His academic work includes a research assistant professorship at Stony Brook University, where he remains a voluntary assistant professor of research, and an earlier research fellowship from the Boehringer Ingelheim Fonds.
CP
Charlie PettyNamed on SEC filing
SW
Steven WinickNamed on SEC filing
JH
Jill HoweNamed on SEC filing
PG
Paul GrintinExecutive Chairman & Interim CEOGrint has led several biopharmaceutical companies, serving as CEO of AmpliPhi Biosciences and as President and CEO of Regulus Therapeutics. He also chairs CRISPR QC, is an entrepreneur in residence at the University of California San Diego, and has served on the boards of Persephone Biosciences, Inhibikase Therapeutics, and Synedgen.
TC
Tyler CookNamed on SEC filing
LR
Lori Rudolph-OwenNamed on SEC filing
Board
GR
Investors · 3
Reported raises · per SEC filings
Form D private placements$25M disclosed across 1 round · 2023
▶$25MraisedFeb 2023 · 5 investors · BiotechnologyRule 506(b)
▶$25MraisedFeb 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charlie PettyDirector
- Steven WinickDirector
- Jill HoweDirector
- John Robert ColemanExecutive Officer, Director
- Steffen MuellerDirector
- Paul GrintDirector
- Glenn RockmanDirector
- Tyler CookExecutive Officer
- Lori Rudolph-OwenDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
GigaGen3 shared keywordsGigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
Transcode Therapeutics3 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Companies competing with Codagenix for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 13 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $999.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.9M |
| U.S. ArmyArmy | Phase II | 2019 | $947.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| Department of Agriculture (USDA) | Phase II | 2017 | $592.9K |
| U.S. ArmyArmy | Phase I | 2017 | $148.9K |
| Department of Agriculture (USDA) | Phase II | 2016 | $597.7K |
| Department of Agriculture (USDA) | Phase I | 2016 | $99.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $222.7K |
| Department of Agriculture (USDA) | Phase I | 2015 | $99.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $596.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $399.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $600K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Codagenix do?
- Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses. The company applies this platform in clinical development, drawing on expertise in virology, computational science, and patient care.
- Who founded Codagenix?
- Codagenix was founded by John Robert Coleman, Steffen Mueller in 2011.
- Who are Codagenix's investors?
- Codagenix's investors include Adjuvant Capital, In-Q-Tel, Topspin Partners.
- How much funding has Codagenix raised?
- Codagenix has disclosed $25M raised across 1 round.
- Where is Codagenix headquartered?
- Codagenix is headquartered in Farmingdale, US.